Clinical Trial Detail

NCT ID NCT02193347
Title IDH1 Peptide Vaccine for Recurrent Grade II Glioma (RESIST)
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Gary Archer Ph.D.
Indications

malignant glioma

Therapies

Montanide ISA 51 + PEPIDH1M vaccine + Sargramostim + Temozolomide

Age Groups: adult senior

Additional content available in CKB BOOST